Seoul Pharma Co., Ltd (KOSDAQ:018680)

Market Cap	30.31B -15.2%
Revenue (ttm)	52.15B -2.7%
Net Income	753.64M -55.6%
EPS	n/a
Shares Out	11.66M
PE Ratio	40.22
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,626
Average Volume	11,306
Open	2,805.00
Previous Close	2,730.00
Day's Range	2,650.00 - 2,805.00
52-Week Range	2,310.00 - 4,205.00
Beta	0.51
RSI	40.57
Earnings Date	n/a

About Seoul Pharma

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer’ disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and m...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 172
• Stock Exchange: KOSDAQ
• Ticker Symbol: 018680

Financial Performance

In 2025, Seoul Pharma's revenue was 52.15 billion, a decrease of -2.67% compared to the previous year's 53.58 billion. Earnings were 753.64 million, a decrease of -55.63%.